This site is intended for UK healthcare professionals
Medscape UK Univadis Logo
Medscape UK Univadis Logo
Clinical Summary

Resveratrol may reduce albuminuria in patients with diabetic nephropathy

Takeaway

  • Resveratrol may be an effective adjunct to angiotensin receptor blockers (ARBs) for reducing urinary albumin excretion in patients with diabetic nephropathy.

Why this matters

  • Resveratrol is naturally occurring and derived from plants, and is widely reported for its anti-inflammatory, antioxidant, antiapoptotic and cytoprotective effects but no studies have evaluated its effects on albuminuria.

Study design

  • Randomised controlled trial of 60 patients (resveratrol group, n=30; placebo, n=30) with type 2 diabetes and albuminuria between March 2016 and February 2017.
  • Patients received either resveratrol (500 mg/day) or placebo for 90 days; losartan (12.5 mg/day) was administered to all patients.
  • Funding: Shiraz University of Medical Sciences.

Key results

  • Significant reduction in mean urine albumin/creatinine ratio was observed in resveratrol group (−46.4 mg/g; P<.001) vs placebo group (29.9 mg/g; P<.001) and remained significant after adjustments (P<.001).
  • In the resveratrol group, increase in levels of nitric oxide (NO; P<.001), superoxide dismutase (P<.001), glutathione peroxidase (P<.001) and catalase (P<.001), and significant decrease in malondialdehyde (P=.03) was observed.
  • Every 1 cm decrease in waist circumference and 1 μmol/L increase in NO was associated with 9.4 mg/g and 4.0 mg/g reduction in urine albumin/creatinine ratio, respectively.

Limitations

  • Short duration of study.
  • Inflammatory markers were not measured.

References


YOU MAY ALSO LIKE